FDA approves ofatumumab for the treatment of relapsing forms of multiple sclerosis

The US FDA has approved ofatumumab for the treatment of clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It can be self-administered once monthly via the Sensoready® autoinjector pen.

SPS commentary:

Ofatumumab is a fully humanised, high affinity monoclonal antibody targeted against CD20 cell surface antigen of B-cell membranes. An application for its approval in the EU was filed in February 2020.


Biospace Inc.